Acquisition Opportunity AMI was acquired by Schott AG in 2021, signaling integration into a larger diagnostics ecosystem. This presents a potential cross-sell angle for Schott’s broader customer base, leveraging AMI's microarray and biosensor manufacturing capabilities to expand contract manufacturing offerings.

Niche Manufacturing Specializes in custom multiplex nucleic acid and protein microarrays and biosensors for disease diagnostics with devices fabricated on glass, plastic, and semiconductors. Target labs and diagnostic centers seeking high-complexity, high-mix manufacturing could be inclined to partner for specialized assay development and scaling.

Recent Scanner Enhancements Multiple announcements of improved microarray scanners suggest ongoing product development and customer value delivery. This creates upsell potential for scanner maintenance, data analysis software, and bundled lab equipment services with existing microarray manufacturing contracts.

Strategic Partnerships Past collaborations with Novacyt and Primerdesign indicate established ecosystem partnerships in SNP assay development. There is opportunity to re-engage or formalize co-development deals with diagnostics players seeking end-to-end SNP, microarray, or POC solution capabilities.

Smaller Scale, High Growth With 2-10 employees and revenue in the low millions, AMI represents a boutique, agile contractor ideal for pilot programs, rapid prototyping, and scalable manufacturing for emerging diagnostics startups looking for customizable microarray services without large-cap costs.